All posts

CannTrust is a leader in the cannabis oil market, Beacon Securities says

With CannTrust’s (CannTrust Stock Qupte, Chart TSX:TRST) announcement that it has launched three new cannabis extract formulations, analyst Russell Stanley of Beacon Securities is staying bullish on the cannabis company, saying TRST still trades at a marked discount to its peers.

On Wednesday, Stanley reiterated his “Buy” recommendation and $15.00 target price, representing a projected 12-month return of 51 per cent at the time of publication.

On Wednesday morning, Canadian LP CannTrust announced the three new formulations, geared at meeting the growing demand for cannabis oil in the medical marijuana market. One is a high-dose CBD capsule, another is high-dose CBD in drop formula and the third is a low-dose 1:1 CBD and THC capsule.

In his note to clients, Stanley points out that extract products have a number of advantages over smokable products (more dose control and easier to administer, for example) and that CannTrust’s focus on extracts has done well by them so far.

“CannTrust has traditionally been a market leader in extract/oil sales, with management estimating its market share at 27 per cent for Q4/18. Moreover, we believe development of higher value products will be a critical driver of success as new product forms are legalized (e.g. edibles, beverages, etc). CannTrust’s continued leadership here bodes well for the company’s success on that front,” he says.

Stanley maintains that TRST is trading at 15x his 2020 EBITDA estimate, which represents a 61-per-cent discount to the 38x average among cannabis companies with a $1 billion-plus market cap. He says that TRST also trades at a 78-per-cent discount to the 67x average at which US-listed cannabis companies trade.

The analyst notes that the stock seems to have “found its footing” after the market responded negatively to the company’s Q4/18 financial results.

“The company has made solid progress on developing its outdoor grow initiative and management is predicting a meaningful contribution from its first outdoor harvest in 2019, which should make our forecasts for this year very achievable,” says Stanley. “We continue to view TRST as one of a select few Canadian producers that offers low-cost production potential with demonstrated strength in developing higher value products.”

Tagged with: trst
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Verano Holdings is undervalued, Haywood says

Haywood Capital Markets analyst Neal Gilmer says Verano Holdings (Verano Holdings Stock Quote, Chart, News, Analysts, Financials NEO:VRNO) is staying… [Read More]

2 days ago

Knight Therapeutics is a buy, Stifel says

Knight Therapeutics (Knight Therapeutics Stock Quote, Chart, News, Analysts, Financials TSXV:GUD) is continuing to build momentum, according to Stifel Nicolaus… [Read More]

2 days ago

Groupon wins price target raise at Roth

Roth Capital Partners has raised its price target on Groupon (Groupon Inc Stock Quote, Chart, News, Analysts, Financials NASDAQ:GRPN) to… [Read More]

2 days ago

Trulieve Cannabis is a buy, Beacon says

Trulieve Cannabis (Trulieve Cannabis Stock Quote, Chart, News, Analysts, Financials CSE:TRUL) delivered a strong start to fiscal 2025, beating high-end… [Read More]

2 days ago

Green Thumb Industries should be a core holding for cannabis investors, analyst says

Green Thumb Industries (Green Thumb Industries Stock Quote, Chart, News, Analysts, Financials CSE:GTII) delivered a steady first quarter and remains… [Read More]

2 days ago

5N Plus just delivered an “exceptional” quarter, this analyst says

5N Plus (5N Plus Stock Quote, Chart, News, Analysts, Financials TSX:VNP) blew past expectations in the first quarter of 2025,… [Read More]

2 days ago